Details:
Under the terms of the agreement, Disc Medicine will obtain exclusive, global rights to and be responsible for all development, manufacturing, and commercialization of bitopertin and related back up compounds.
Lead Product(s): Bitopertin
Therapeutic Area: Rare Diseases and Disorders Product Name: RO4917838
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Disc medicine
Deal Size: $200.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement May 27, 2021